The transwell assay, MTT assay, and expression level of MMP2 and MMP9 revealed that knockdown of NUCB2 with special shRNA inhibits invasion and proliferation in bladder cancer cells which were similar to other reports in breast [20], colon [25], and prostate [23] cancer and in clear cell renal cell (ccRCC) carcinoma [21]. Here, NUCB2 is linked to urinary bladder carcinoma.